Fondazione IRCCS Istituto Nazionale dei Tumori, Milano: Carcinoma, Renal Cell trials

The registry lists 10 Carcinoma, Renal Cell studies with Fondazione IRCCS Istituto Nazionale dei Tumori, Milano as lead sponsor. 1 are open to participants now and 0 have results posted.

Phase 2 5Phase 3 1No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Quantifying Systemic Immunosuppression to Personalize Cancer TherapyRecruitingNCT05621837
• Multiomics Approach in Metastatic Clear Renal Cell CarcnomaActive, not recruitingNCT05782400
• Collecting Ducts Carcinoma: in Depth Exploration and Biologically Driven Therapy (CICERONE)Status unknownNCT05372302
• Prospective Translational Study Investigating Predictors of Outcome in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab (I-Rene Trial)Status unknownNCT04891055
• Prospective Translational Study Investigating Possible Molecular prEdictors of Resistance to First-Line pazopanIbCompletedNCT04462445Phase 2
• A Study of CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinomaCompletedNCT03463681Phase 2
• caBozantinib in cOllectiNg ductS Renal Cell cArcInomaCompletedNCT03354884Phase 2
• Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers DiscoveryTerminatedNCT02535351Phase 3
• Second Line Sorafenib After Pazopanib in Patients With RCCTerminatedNCT02122003Phase 2
• Evaluate the Efficacy of Sorafenib in Renal Cell Carcinoma Patients After a Radical Resection of the MetastasesStatus unknownNCT01444807Phase 2